Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$178.43
-0.33-0.18%
À la fermeture: -
$178.60
0.170.10%
Après les heures de négociation: 7:59 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Johnson & Johnson a un objectif de cours consensus de $173.68, basé sur les évaluations des 19 analystes. Le plus élevé est de $215 attribué par Cantor Fitzgerald le octobre 16, 2024, et le plus bas est de $150 attribué par Daiwa Capital le juillet 23, 2024. Les 3 dernières évaluations d'analystes ont été publiées par Citigroup, Barclays et RBC Capital le août 21, 2025, juillet 17, 2025 et juillet 17, 2025. Avec un objectif de cours moyen de $187 entre Citigroup, Barclays et RBC Capital, il y a une variation implicite de 4.70% upside pour Johnson & Johnson à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Citigroup
Barclays
RBC Capital
Guggenheim
UBS
1calculé à partir des notes des analystes
Notes d'analystes pour Johnson & Johnson
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/21/2025 | 11.98% | Citigroup | $185 → $200 | Maintains | Buy | |||
07/17/2025 | -1.46% | Barclays | $165 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | 3.58% | RBC Capital | $181 → $185 | Maintains | Outperform | |||
07/17/2025 | -6.49% | Guggenheim | $164 → $167 | Maintains | Neutral | |||
07/17/2025 | 6.38% | UBS | $180 → $190 | Maintains | Buy | |||
07/17/2025 | -1.46% | Morgan Stanley | $171 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | -2.02% | B of A Securities | $161 → $175 | Maintains | Neutral | |||
07/10/2025 | -4.26% | Morgan Stanley | $169 → $171 | Maintains | Equal-Weight | |||
06/05/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
05/13/2025 | -14.33% | Leerink Partners | $169 → $153 | Downgrade | Outperform → Market Perform | |||
04/17/2025 | -7.61% | Barclays | $166 → $165 | Maintains | Equal-Weight | |||
04/16/2025 | -8.17% | Raymond James | $162 → $164 | Maintains | Outperform | |||
04/16/2025 | -5.38% | Morgan Stanley | $164 → $169 | Maintains | Equal-Weight | |||
04/16/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/14/2025 | -9.29% | Raymond James | $165 → $162 | Maintains | Outperform | |||
04/10/2025 | -10.97% | B of A Securities | $171 → $159 | Maintains | Neutral | |||
04/09/2025 | -8.17% | Morgan Stanley | $163 → $164 | Maintains | Equal-Weight | |||
04/09/2025 | -3.7% | Goldman Sachs | $157 → $172 | Upgrade | Neutral → Buy | |||
04/03/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/12/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/10/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/05/2025 | -4.26% | B of A Securities | $159 → $171 | Maintains | Neutral | |||
02/19/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/03/2025 | -7.05% | Guggenheim | $162 → $166 | Maintains | Neutral | |||
01/28/2025 | -7.05% | Barclays | $159 → $166 | Maintains | Equal-Weight | |||
01/23/2025 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/23/2025 | -8.73% | Morgan Stanley | $175 → $163 | Maintains | Equal-Weight | |||
01/23/2025 | -13.21% | Stifel | $170 → $155 | Maintains | Hold | |||
01/23/2025 | -5.38% | Leerink Partners | $182 → $169 | Maintains | Outperform | |||
01/23/2025 | -14.89% | Wells Fargo | $166 → $152 | Maintains | Equal-Weight | |||
01/23/2025 | -7.61% | Raymond James | $170 → $165 | Maintains | Outperform | |||
01/23/2025 | -10.97% | B of A Securities | $160 → $159 | Maintains | Neutral | |||
01/17/2025 | -10.41% | B of A Securities | $166 → $160 | Maintains | Neutral | |||
12/11/2024 | -2.02% | Citigroup | $185 → $175 | Maintains | Buy | |||
12/10/2024 | -7.05% | B of A Securities | → $166 | Reinstates | → Neutral | |||
11/15/2024 | 6.38% | Wolfe Research | → $190 | Initiates | → Outperform | |||
11/06/2024 | -9.29% | Guggenheim | $156 → $162 | Maintains | Neutral | |||
10/16/2024 | 3.58% | Citigroup | $180 → $185 | Maintains | Buy | |||
10/16/2024 | -7.05% | Wells Fargo | $163 → $166 | Maintains | Equal-Weight | |||
10/16/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/16/2024 | 1.34% | RBC Capital | $178 → $181 | Maintains | Outperform | |||
10/16/2024 | -2.02% | Morgan Stanley | $169 → $175 | Maintains | Equal-Weight | |||
10/10/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/08/2024 | -0.34% | RBC Capital | $175 → $178 | Maintains | Outperform | |||
09/30/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/23/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/20/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
09/19/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/03/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
08/05/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/23/2024 | -16.01% | Daiwa Capital | $160 → $150 | Downgrade | Outperform → Neutral | |||
07/19/2024 | -13.21% | Goldman Sachs | $160 → $155 | Maintains | Neutral | |||
07/18/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/18/2024 | 3.58% | TD Cowen | $195 → $185 | Maintains | Buy | |||
07/18/2024 | -5.38% | Morgan Stanley | $167 → $169 | Maintains | Equal-Weight | |||
07/01/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/17/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
06/04/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/22/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/16/2024 | -2.02% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/06/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/18/2024 | -4.82% | HSBC | $169 → $170 | Upgrade | Hold → Buy | |||
04/17/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/17/2024 | -6.49% | Morgan Stanley | $168 → $167 | Maintains | Equal-Weight | |||
04/17/2024 | -2.02% | RBC Capital | $181 → $175 | Maintains | Outperform | |||
04/17/2024 | -4.82% | B of A Securities | $180 → $170 | Maintains | Neutral | |||
04/15/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
03/13/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/28/2024 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/20/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/06/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 1.34% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/24/2024 | -5.38% | Morgan Stanley | $170 → $169 | Maintains | Equal-Weight | |||
01/23/2024 | 20.38% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
01/09/2024 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/03/2024 | -2.02% | Raymond James | $172 → $175 | Maintains | Outperform | |||
12/13/2023 | -8.73% | Wells Fargo | $170 → $163 | Downgrade | Overweight → Equal-Weight | |||
12/06/2023 | 1.34% | RBC Capital | $178 → $181 | Maintains | Outperform | |||
12/01/2023 | -0.34% | RBC Capital | $178 → $178 | Reiterates | Outperform → Outperform | |||
12/01/2023 | 0.78% | UBS | → $180 | Upgrade | Neutral → Buy | |||
11/20/2023 | 20.38% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
11/17/2023 | 20.38% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
10/23/2023 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/18/2023 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/18/2023 | -3.7% | Raymond James | $179 → $172 | Maintains | Outperform | |||
10/18/2023 | -4.26% | Morgan Stanley | $174 → $171 | Maintains | Equal-Weight | |||
10/12/2023 | -9.29% | Barclays | $158 → $162 | Maintains | Equal-Weight | |||
10/11/2023 | 20.38% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/11/2023 | -2.58% | Morgan Stanley | $172 → $174 | Maintains | Equal-Weight | |||
10/09/2023 | 20.38% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
10/05/2023 | -0.34% | RBC Capital | → $178 | Initiates | → Outperform |
FAQ
Quel est le cours indicatif de l'action Johnson & Johnson (JNJ) ?
Le dernier objectif de prix pour Johnson & Johnson (NYSE:JNJ) a été rapporté par Citigroup le août 21, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $200.00 s'attendant à ce que JNJ se rise dans les 12 prochains mois (un possible changement de 11.98% upside). 52 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Johnson & Johnson (JNJ) ?
La dernière note d'analyste pour Johnson & Johnson (NYSE:JNJ) a été fournie par Citigroup, et Johnson & Johnson maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Johnson & Johnson (JNJ) ?
La dernière amélioration pour Johnson & Johnson a eu lieu le avril 9, 2025 lorsque Goldman Sachs a augmenté leur objectif de prix à $172. Goldman Sachs avait précédemment a neutral pour Johnson & Johnson.
Quand a eu lieu la dernière dégradation pour Johnson & Johnson (JNJ) ?
La dernière réduction pour Johnson & Johnson a eu lieu le mai 13, 2025 lorsque Leerink Partners a changé leur objectif de prix de $169 à $153 pour Johnson & Johnson.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Johnson & Johnson (JNJ) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Johnson & Johnson, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Johnson & Johnson a été déposée le août 21, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 21, 2026.
La note d'analyste pour Johnson & Johnson (JNJ) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Johnson & Johnson (JNJ) était un maintenu avec un objectif de prix de $185.00 à $200.00. Le prix actuel de Johnson & Johnson (JNJ) est de $178.60, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.